Palvella Therapeutics, Inc. filed a Form 8-K on November 19, 2026, announcing a corporate presentation regarding its QTORIN® docetaxel program. The filing indicates that the company will host a conference call with investors at 8:30 a.m. Eastern Time on the same day to present the third product candidate developed from its QTORIN® platform. The presentation and live event can be accessed via a link provided in the filing.

The presentation focuses on QTORIN® docetaxel as a potential first-in-disease therapy for Extramammary Paget’s Disease (EMPD). The company states that EMPD is a serious, rare condition with no FDA-approved therapies. The filing notes that the current primary treatment for EMPD is surgery, and the company aims to transform the treatment paradigm to a first-line, localized topical therapy.

The filing includes data from human clinical evidence regarding I.V. docetaxel, citing a study with 93 patients that reported an Objective Response Rate (ORR) of 51.6%. However, the presentation also notes that 24.7% of patients discontinued treatment due to adverse events and that 52.7% experienced Grade 3 neutropenia. The company states that QTORIN® is designed to overcome formulation barriers associated with docetaxel, specifically addressing hydrophobicity, poor skin penetration, and instability. The filing indicates that the formulation is designed to limit systemic absorption and selectively target the epidermis.

Regarding the clinical development plan, the filing states that Palvella plans to leverage the 505(b)(2) regulatory pathway. The company has initiated IND-enabling study activities and plans to seek meetings with the U.S. Food and Drug Administration. The filing notes that a meeting with the FDA is planned for the first half of 2027, with the goal of advancing to a Phase 2 study.